Affording the New Obesity Drugs? We Can't Afford Not to

Published cost-effectiveness analyses of GLP-1 receptor agonists for obesity and diabetes have shown mixed results, but their wide-ranging benefits may have been sold short.
Medscape Medical News

source https://www.medscape.com/viewarticle/994635?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost